Wagner Lecture: PET & MRI: A match made in heaven, or the odd couple?

Sunday, June 5 | 8:30 AM - 10:15 AM
Ballroom A

Overview:
While CT led the way anatomically, PET has been our principal means of molecular imaging, hence their integration was a natural development. Nuclear MR has also seen steady growth, offering high resolution with increasing physiologic capabilities, though without PET's exquisite sensitivity and diversity. This period of 'parallel play' may be ending, as technical solutions to PET/MRI integration are found, and applications taking advantage of their complimentary characteristics identified. This talk will explore the potentials and pitfalls of combined studies using these two distinct nuclear imaging methods.

Speaker is:
Bruce R. Rosen, MD, PhD, Harvard Medical School in Boston.

 

Around the web

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.